반응식
Br[C:2]1[CH:11]=[CH:10][C:9]2[N:8]=[CH:7][C:6]3[N:12]([CH3:23])[C:13](=[O:22])[N:14]([C:15]4[C:16]([CH3:21])=[N:17][N:18]([CH3:20])[CH:19]=4)[C:5]=3[C:4]=2[CH:3]=1.[CH2:24]([O:31][CH2:32][CH2:33][O:34][C:35]1[CH:40]=[CH:39][C:38](B2OC(C)(C)C(C)(C)O2)=[CH:37][N:36]=1)[C:25]1[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=1>>[CH2:24]([O:31][CH2:32][CH2:33][O:34][C:35]1[N:36]=[CH:37][C:38]([C:2]2[CH:11]=[CH:10][C:9]3[N:8]=[CH:7][C:6]4[N:12]([CH3:23])[C:13](=[O:22])[N:14]([C:15]5[C:16]([CH3:21])=[N:17][N:18]([CH3:20])[CH:19]=5)[C:5]=4[C:4]=3[CH:3]=2)=[CH:39][CH:40]=1)[C:25]1[CH:26]=[CH:27][CH:28]=[CH:29][CH:30]=1참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A, 50 mg, 0.132 mmol) and 2-(2-benzyloxy-ethoxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (Stage 19.1.1, 65 mg, 0.184 mmol) to give the title compound as a white solid. (HPLC: tR 3.12 min (Method A); M+H=521 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.95 (s, 1H), 8.33-8.24 (m, 1H), 8.16-8.05 (m, 2H), 7.93-7.86 (m, 1H), 7.81-7.75 (m, 1H), 7.51-7.45 (m, 1H), 7.40-7.22 (m, 5H), 7.01-6.93 (m, 1H), 4.55 (s, 2H), 4.47 (t, 2H), 3.92 (s, 3H), 3.78 (t, 2H), 3.57 (s, 3H), 1.97 (s, 3H))
후처리
- customThe title compound was synthesized in a similar manner
출처 및 근거
- ORD 기록
- ord-3fcd81c8195e4ebd856c9a6c18013b26
- 출처 데이터셋
- uspto-grants-2013_07
- 특허 번호
- US08476294B2
연결된 노트
불러오는 중…